Evidence map›Paper›PMID 35478863›Full record

ArticleRSC advances2021

Detection of SARS-CoV-2 and its S and N proteins using surface enhanced Raman spectroscopy.

John Eder Sanchez, Sierra A Jaramillo, Erik Settles, J Jesus Velazquez Salazar, Alexander Lehr, Javier Gonzalez, Carmen Rodríguez Aranda, Hugo R Navarro-Contreras, Marlee O Raniere, Maxx Harvey and 5 more

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 82 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

John Eder SanchezApplied Physics and Materials Science Department (APMS), Northern Arizona University AZ USA Miguel.Yacaman@nau.edu.
Sierra A JaramilloPathogen and Microbiome Institute, Northern Arizona University AZ USA.
Erik SettlesPathogen and Microbiome Institute, Northern Arizona University AZ USA.
J Jesus Velazquez SalazarApplied Physics and Materials Science Department (APMS), Northern Arizona University AZ USA Miguel.Yacaman@nau.edu.
Alexander LehrApplied Physics and Materials Science Department (APMS), Northern Arizona University AZ USA Miguel.Yacaman@nau.edu.
Javier GonzalezCentro de Investigación Aplicada en Ciencia y Tecnología (CIACYT), Universidad Autonoma de San Luis Potosi Mexico.
Carmen Rodríguez ArandaCentro de Investigación Aplicada en Ciencia y Tecnología (CIACYT), Universidad Autonoma de San Luis Potosi Mexico.ORCID https://orcid.org/0000-0003-0632-2265
Hugo R Navarro-ContrerasCentro de Investigación Aplicada en Ciencia y Tecnología (CIACYT), Universidad Autonoma de San Luis Potosi Mexico.ORCID https://orcid.org/0000-0003-0333-0024
Marlee O RanierePathogen and Microbiome Institute, Northern Arizona University AZ USA.
Maxx HarveyPathogen and Microbiome Institute, Northern Arizona University AZ USA.
David M WagnerPathogen and Microbiome Institute, Northern Arizona University AZ USA.ORCID https://orcid.org/0000-0003-2684-6007
Andrew KoppischDepartment of Chemistry, Northern, Arizona University AZ USA.
Robert KellarDepartment of Biological Sciences, Northern Arizona University AZ USA.
Paul KeimPathogen and Microbiome Institute, Northern Arizona University AZ USA.
Miguel Jose YacamanApplied Physics and Materials Science Department (APMS), Northern Arizona University AZ USA Miguel.Yacaman@nau.edu.ORCID https://orcid.org/0000-0002-2945-6509
Northern Arizona University · USAutonomous University of San Luis Potosí · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic demonstrated the critical need for accurate and rapid testing for virus detection. This need has generated a high number of new testing methods aimed at replacing RT-PCR, which is the golden standard for testing. Most of the testing techniques are based on biochemistry methods and require chemicals that are often expensive and the supply might become scarce in a large crisis. In the present paper we suggest the use of methods based on physics that leverage novel nanomaterials. We demonstrate that using Surface Enhanced Raman Spectroscopy (SERS) of virion particles a very distinct spectroscopic signature of the SARS-CoV-2 virus can be obtained. We demonstrate that the spectra are mainly composed by signals from the spike (S) and nucleocapsid (N) proteins. It is believed that a clinical test using SERS can be developed. The test will be fast, inexpensive, and reliable. It is also clear that SERS can be used for analysis of structural changes on the S and N proteins. This will be an example of application of nanotechnology and properties of nanoparticles for health and social related matters.

Identifiers

PMID35478863
PMCPMC9037103
OpenAlexW3185618849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.